Please assess the completion status of the following clinical trial:

Trial Title: Post Marketing Surveillance Study to Observe Safety and Efficacy of Inlyta in South Korea

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: CASE_ONLY
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Patients diagnosed as advanced RCC after failure of one prior systemic therapy.~Exclusion Criteria:~* Any patient who does not agree that Pfizer or companies working on behalf of Pfizer can use his/her information.~* Patients with hypersensitivity to axitinib or to any other component of INLYTA® .~* Patients under 18.~* Pregnant women.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Patients who are using Axitinib (Type: None): None

Based on this trial design, predict the completion outcome and termination type (if applicable).